Since its inception in , Lescarden has devoted its resources to fund research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis and cancer applications. In the ensuing years, significant studies substantiated the ability of Catrix, Lescarden s proprietary cartilage powder, to function as a biological response modifier by stimulating the body s immune system. This response has significant, demonstrated benefits for chronic wound management, and has been investigated as a potential treatment for certain types of cancer. Further studies indicated that Catrix has potent anti inflammatory properties that could also be effective against diseases such as arthritis, scleroderma and psoriasis. lt br / gt lt br / gt With a solid clinical platform, the Company in recent years has focused its strategy toward pursuing marketing and licensing opportunities for fully developed products that have received patents and are ready for commercialization.
Quote | Lescarden Inc (OTCMKTS:LCAR)
Last: | $1e-06 |
---|---|
Change Percent: | 0.0% |
Open: | $1e-06 |
Close: | $1e-06 |
High: | $1e-06 |
Low: | $1e-06 |
Volume: | 4,000 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Lescarden Inc (OTCMKTS:LCAR)
Message Board Posts | Lescarden Inc (OTCMKTS:LCAR)
Subject | By | Source | When |
---|---|---|---|
LCAR: SEC registration revoked. | Renee | investorshub | 03/09/2023 10:02:05 PM |
LCAR: SEC Admin. Proceeding for severely delinquent Financials: | Renee | investorshub | 08/18/2022 4:03:34 PM |
Looks like the smart money is piling in. | r189 | investorshub | 01/02/2018 8:02:33 AM |
Glenmede Trust Co becomes a shareholder owning 90k | r189 | investorshub | 01/02/2018 3:48:22 AM |
Some nice volume here today finally. Anyone | ShaneO19 | investorshub | 12/04/2017 3:07:01 PM |